May 2015 Vol. 17 Issue 5
ECHO
THE EMPLOYEE NEWSLETTER OF HOSPITAL FOR SPECIAL SURGERY
Lionel B. Ivashkiv, M.D. Appointed Chief Scientific Officer esearch is a cornerstone of our vision
Leadership in Research SS scientists
R
H
than 200 scientists and staff work to identify
professional organizations
causes of musculoskeletal and autoimmune
throughout the years. One
diseases and develop effective approaches for
of these is the Orthopedic
diagnoses, treatment and long-term benefits to
Research Society (ORS),
patients. Our scientists’ and physicians’ research
an organization whose
continues to shape the future of musculoskeletal
purpose is to promote,
and mission – it is critical to enhanced
have held
patient care and HSS’ impact on the
research
fields of orthopedics and rheumatology. More
leadership positions in
Dr. Bostrom and Dr. Goldring at the ORS Annual Meeting
medicine and the foundation for better treatments
support, develop and encourage research in ortho-
and patient care.
paedics and musculoskeletal disease and related
HSS recently announced that Lionel B. Ivashkiv,
disciplines and to provide a forum for dissemination of
M.D., premier scientist in autoimmune, inflammatory
knowledge in the fields. Five HSS scientists have been
and musculoskeletal diseases, would serve as the
president of this prestigious organization dedicated to Dr. Goldring (left) and Dr. Ivashkiv
the advancement of orthopaedic research.
the David H. Koch Chair in Arthritis and Tissue
enhancement of HSS’ position as a leader in
The most recent president inaugurated is Mathias
Degeneration and associate chief scientific officer,
musculoskeletal and autoimmune disease research.
P. Bostrom, M.D., senior clinician scientist, who
Dr. Ivashkiv succeeds Steven R. Goldring, M.D.,
“What’s unique about HSS is the team-based
transitioned into the role at a ceremony at the ORS
who has served in the role since 2006. Dr. Ivashkiv
approach to research and the linkage between
Annual Meeting that took place following the AAOS
assumed his new role on June 1 and this also marked
basic science and clinical research,” he said.
in March. Dr. Bostrom took over from Mary Goldring,
his 23rd anniversary at HSS.
“We are committed to asking meaningful scientific
Ph.D., senior scientist and co-director of the Tissue
questions and then figuring out a way to apply
Engineering Regeneration and Repair Program, who
advances in knowledge to impact patient care.”
was president during the prior year.
“During an exceptional tenure, Dr. Goldring has
The Research Division experienced unprecedented
A major aspect of the president’s leadership role is
fostered a creative and productive scientific
growth under Dr. Goldring’s leadership in the past
to head the ORS Board of Directors, which provides
environment, attracted new scientists and built
nine years. Some highlights include:
governance and direction; ensures that the mission of
the Research Division into the world-leader in
• HSS became an NIH Network Partner for
the ORS stays on course; approves activities and new
Hospital’s third chief scientific officer. Currently
Dr. Ivashkiv will build on a history of research and the infrastructure developed by Dr. Goldring.
musculoskeletal science it is today,” said
Rheumatoid Arthritis and Lupus
initiatives of the committees; recommends changes to
Lou Shapiro, president and CEO. “We look
The National Institutes of Health (NIH) awarded
the Bylaws; oversees the ORS Annual Meeting; formu-
forward to working with Dr. Ivashkiv to continue
grants to 11 research groups across the United
lates the strategic plan; and represents its members.
building and enhancing our Research Division.”
States to establish the Accelerating Medicines
“I’m honored to take on this role with the ORS and
“Dr. Ivashkiv’s career as a scientist includes major
Partnership in Rheumatoid Arthritis and Lupus
lead this amazing organization as we continue
contributions to the understanding of inflammatory
(AMP RA/Lupus) Network. HSS was selected as
working together to advance musculoskeletal research
mechanisms in autoimmune and musculoskeletal
a Research Site with Drs. Vivian Bykerk, Lionel
worldwide,” said Dr. Bostrom. “We are embarking on
disorders,” said Todd J. Albert, M.D., surgeon-in-chief
Ivashkiv, and Alessandra B. Pernis from the
the launch of a new strategic plan and I’m excited
and medical director. “He has outstanding natural
Research Division and Drs. Figgie, Sculco, Marx
about moving forward.” With the transition of
leadership skills and has earned the respect of his
and Hotchkiss from the Orthopaedic department
leadership from Dr. Goldring to Dr. Bostrom, the
colleagues both here at HSS and abroad which makes
leading the research initiative.
previous five-year strategic plan was concluded.
him ideally suited to lead our Research Division.”
• Creation of the David Z. Rosensweig Genomics
The new plan will focus on areas of funding, strategic partnerships, diversity and professional
“I am honored to work even more closely with
Research Center
colleagues who are committed to building on
With a $5.6 million grant from the Tow Foundation,
development, and adaptation to change. “Our new
HSS’ tradition of interdisciplinary translational
HSS created The David Z. Rosensweig Genomics
plan builds on the strong foundation put in place over
research,” said Dr. Ivashkiv. “Together we will
Research Center, under the direction of Dr.
CONTINUED on page 2
advance the Hospital’s research mission to
Ivashkiv. The goals are to define the regulation
translate breakthrough findings into new ways of
of genes associated with autoimmune and
treating and preventing serious orthopedic and
inflammatory diseases, and to develop more
rheumatic conditions.”
effective therapies for rheumatoid arthritis and
In this new role, Dr. Ivashkiv will work to develop and execute strategic plans to continue the
systemic lupus erythematosus.
CONTINUED on page 2
Inside
2 3
At HSS, It’s Safety First Epic: One patient. One record. One HSS.